The latest report by IMARC Group, titled “Microbiome Sequencing Services Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global microbiome sequencing services market size reached US$ 1,846.3 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 5,568.4 Million by 2028, exhibiting a growth rate (CAGR) of 20% during 2023-2028. Microbiome sequencing services represent a crucial component of modern biological research and healthcare. These services involve the comprehensive analysis of microbial communities inhabiting various environments, such as the human gut, soil, water, and more. The process employs advanced genomic techniques to identify and characterize the diverse microorganisms present within a given sample. By leveraging high-throughput DNA sequencing technologies, microbiome sequencing enables researchers and healthcare professionals to gain invaluable insights into the composition and functional potential of these microbial populations. For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/microbiome-sequencing-services-market/requestsample< /span> Microbiome Sequencing Services Market Trends and Drivers: Rapid developments in DNA sequencing technologies, such as Next-Generation Sequencing (NGS), have made microbiome sequencing more accessible, cost-effective, and efficient. This has expanded the scope of microbiome research across diverse applications. Additionally, increasing awareness about the critical role the microbiome plays in human health, particularly in relation to conditions like gastrointestinal disorders, obesity, and autoimmune diseases, has fueled research and diagnostic demand. Other than this, the shift toward precision medicine and personalized healthcare has led to a surge in microbiome sequencing. Understanding individual microbiomes can aid in tailoring treatments and therapies. Besides this, microbiome sequencing is also instrumental in agriculture for optimizing crop yields, managing soil health, and enhancing plant resilience. This has garnered attention from the agriculture and agribusiness sectors. In line with this, pharmaceutical companies are increasingly investing in microbiome research to develop innovative drugs and therapies. Microbiome sequencing aids in identifying potential drug targets and understanding drug-microbiome interactions. Furthermore, microbiome sequencing is used to study microbial diversity in various ecosystems, contributing to environmental conservation and management efforts. Report Segmentation: The report has segmented the market into the following categories: Breakup by Technology:
- Sequencing by Synthesis (SBS)
- Sequencing by Ligation (SBL)
- Pyrosequencing
- Sanger Sequencing
- Others
- Outsourced Research
- Internal Research
- Dry Labs
- Wet Labs
- Shotgun Sequencing
- Targeted Gene Sequencing
- RNA Sequencing
- Whole Genome Sequencing
- Others
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutes
- Others
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
- BaseClear B.V.
- Clinical-Microbiomics A/S
- Diversigen Inc (OraSure Technologies Inc.)
- Mérieux NutriSciences
- Metabiomics Corporation (BioSpherex LLC)
- Microbiome Insights Inc.
- Microbiome Therapeutics LLC
- Molecular Research LP
- Molzym GmbH & Co. KG
- Resphera Biosciences LLC
- Shanghai Realbio Technology (RBT) Co. Ltd.
- Zymo Research Corporation